Lates News

Affordable weight loss drug supplier Hims & Hers Health reported a second-quarter revenue of $544.8 million, slightly below analysts' expectations of $552.1 million. Operating expenses for the second quarter were $389.5 million, a 59% decrease from the previous year. The company expects full-year revenue to be between $2.3 billion and $2.4 billion, with analysts' expectations at $2.36 billion. Adjusted EBITDA for the full year is projected to be between $295 million and $335 million, compared to analysts' expectations of $322.1 million. The company anticipates third-quarter revenue to be between $570 million and $590 million, slightly lower than analysts' expectations of $584.2 million.